Antitrust Remedies in M&A: Divestitures, Consent Decrees, and Conduct Remedies

Antitrust remedies in M&A transactions are the mechanism through which regulators convert a potentially anticompetitive merger into one that can close. When the FTC or DOJ concludes that a proposed transaction raises competitive concerns, the agency does not simply approve or block the deal: it engages in a negotiation with the parties over what changes are required to make the transaction acceptable. That negotiation determines whether and on what terms the deal closes, which assets must be sold, what ongoing obligations the merged entity must accept, and who bears the cost of compliance for years after the transaction.

This sub-article is part of the HSR Antitrust M&A Legal Guide. It addresses the full anatomy of antitrust remedies from initial taxonomy through post-decree compliance. Companion articles address the HSR filing requirements and thresholds that trigger agency review and the Second Request investigation process that precedes remedy negotiations in contested transactions.

Acquisition Stars advises on antitrust risk assessment, remedy negotiation strategy, and consent decree compliance in M&A transactions. The analysis below reflects current agency policy and market practice and does not constitute legal advice for any specific transaction.

Remedies Taxonomy: Structural, Behavioral, and Hybrid

Antitrust remedies in merger cases fall into three categories: structural remedies, behavioral remedies, and hybrid remedies that combine elements of both. Each category operates on a different theory of how competition is restored, and each carries different implications for deal execution, post-closing obligations, and the merged entity's operational freedom.

Structural remedies require the parties to divest assets to an independent third-party buyer, thereby creating or preserving a competitor in the relevant market. The divestiture removes the competitive overlap that the agency identified as problematic without requiring the agency to oversee the merged entity's conduct after the remedy is implemented. Once the divestiture closes and the monitoring period for the divestiture agreement expires, the structural remedy is complete, and the merged entity is free to operate without the obligations associated with an ongoing conduct order. The agency's preference for structural remedies rests on this self-executing characteristic: a successful divestiture resolves the competitive harm without creating a long-term regulatory relationship between the agency and the merged entity.

Behavioral remedies leave the transaction intact but impose ongoing obligations on the merged entity's conduct: prohibitions on certain actions, affirmative requirements to provide access or supply, information-sharing restrictions, pricing or contracting constraints, and other conditions designed to prevent the merged entity from exploiting market power that the merger created or enhanced. Behavioral remedies are inherently more difficult to design and enforce than structural remedies because they require the agency to anticipate and define every form of harmful conduct in advance, to monitor compliance over an extended period, and to bring enforcement actions against violations that may be subtle or disputed.

Hybrid remedies pair a structural divestiture with behavioral conditions designed to ensure that the divestiture business can operate effectively or that the merged entity cannot undermine the remedy through post-closing conduct. A hybrid remedy might require the parties to divest a product line while also committing to supply the divested business with an input on defined terms for a transition period, to license technology to the buyer on fair and reasonable terms, and to maintain a firewall preventing the merged entity from accessing the divested business's customer data. The behavioral elements of a hybrid remedy are typically time-limited, expiring once the divested business has achieved competitive independence.

Historical FTC and DOJ Preference for Structural Remedies

The FTC and DOJ have consistently expressed a preference for structural remedies in horizontal mergers, and that preference has been articulated in formal policy statements, agency guidelines, and individual case decisions over several decades. The preference is grounded in both institutional and economic reasoning. From an institutional standpoint, behavioral remedies require the agency to serve as an ongoing regulator of the merged entity's conduct, a role that the agencies are not designed or resourced to perform over the multi-year duration of a typical conduct order. From an economic standpoint, structural remedies address the source of the competitive harm directly by removing or preventing the concentration that would otherwise give the merged entity market power.

The DOJ's 2004 policy guide on merger remedies articulated this preference clearly, stating that structural remedies are preferred because they are relatively clean and certain, require no continuous government involvement in the market, and are less likely to delay the resolution of competitive concerns. The FTC's remedies guidelines have taken a similar position, noting that divestitures that create or preserve a viable competitor provide the most reliable restoration of competition in markets where horizontal overlaps are the source of the competitive concern.

The preference for structural remedies is not absolute. Agencies have accepted stand-alone behavioral remedies in vertical merger cases where the competitive concern does not arise from horizontal overlap and where there is no identifiable asset package whose divestiture would address the harm. Behavioral remedies have also been used in regulated industries where the competitive dynamics are sufficiently defined and monitored that ongoing conduct obligations can be implemented and verified. The telecom and banking sectors have historically been the primary contexts in which the agencies have accepted behavioral remedies as an adequate substitute for structural ones.

The 2023 Policy Shift: Renewed Skepticism of Behavioral Remedies

The Biden administration brought to both the FTC and DOJ a significantly more skeptical stance toward consent decree remedies generally and behavioral remedies specifically. Under Chair Lina Khan, the FTC expressed concern that consent decrees had been used in prior administrations to clear mergers that should have been blocked, and that behavioral remedies in particular provided insufficient protection against competitive harm while imposing monitoring burdens the agency could not sustain. The DOJ Antitrust Division under AAG Jonathan Kanter took a similar position, emphasizing that behavioral remedies in vertical merger cases had a weak empirical record and that the agency would seek structural solutions or litigate rather than accept conduct orders that it did not believe could be effectively enforced.

This policy shift had concrete effects on merger remedy negotiations during 2021 through 2024. Parties who might have expected to resolve competitive concerns through behavioral commitments in prior cycles found agencies unwilling to accept those terms, leading to either expanded divestiture requirements, transaction abandonment, or contested litigation. The agencies also showed increased willingness to require broad divestiture packages that included assets the parties considered central to the deal's rationale, rather than accepting narrowly scoped packages designed to minimize deal disruption.

The 2025 transition to a new administration brought renewed attention to remedy design policy. The incoming FTC and DOJ leadership signaled a more pragmatic approach to remedy negotiations, expressing willingness to consider consent decree settlements in cases where prior leadership would have litigated, and indicating that behavioral remedies in vertical cases would receive fresh consideration when the competitive concern was well-defined and monitorable. Parties navigating antitrust review in 2026 must understand that agency policy on remedy preferences is not static and that the appropriate remedy strategy depends significantly on the current enforcement posture of the reviewing agency. For current context on the broader HSR process, see the HSR filing requirements and thresholds article.

Divestiture Package Assembly: Assets, IP, Employees, and Transition Services

Assembling a divestiture package that satisfies the agency's requirements while minimizing disruption to the overall transaction is one of the most consequential and technically complex aspects of antitrust remedy negotiation. The agency's standard for an adequate divestiture package is whether the package, in the hands of a suitable buyer, would allow that buyer to compete effectively in the relevant market within a reasonable period. Packages that fail this standard result in failed divestitures that neither restore competition nor resolve the parties' regulatory exposure.

A complete divestiture package must address five categories of assets. Physical assets include the plants, equipment, real property, and infrastructure used in the business being divested. These are the most visible component of the package but rarely the most critical. Intellectual property is often more important than physical assets, particularly in technology, pharmaceutical, and consumer products sectors where patents, trade secrets, formulations, and know-how are the source of competitive value. The agency will require that all IP associated with the divested business be included in the package, including improvements developed after signing and before closing. Trademarks associated with the divested products must be included unless the agency accepts a brand-licensing arrangement as a temporary substitute.

Customer relationships and contracts are the third critical component. A divestiture business without its customer base is not a viable competitor; it is a collection of assets that must rebuild relationships from scratch. The agency will expect the parties to include existing customer contracts in the divestiture package and to take reasonable steps to facilitate the transfer of customer relationships to the buyer. Key employees are the fourth component. Employees who carry critical knowledge, customer relationships, or operational expertise cannot be retained by the merged entity if their retention would undermine the divested business's ability to compete. The consent decree typically includes provisions prohibiting the merged entity from soliciting key employees of the divested business for a defined period and may require the parties to use reasonable efforts to encourage key employees to accept employment with the divestiture buyer. Transition services are the fifth component: the merged entity may be required to provide the buyer with specified services, including manufacturing, IT, logistics, or administrative support, for a defined transition period while the buyer establishes independent operational capability.

Identifying a Suitable Buyer: Up-Front vs. Fix-It-First

The agency's approval of a divestiture buyer is a substantive determination, not a procedural formality. The agency evaluates proposed buyers against the same standard applied to the divestiture package itself: whether the buyer has the capability, resources, incentives, and independence required to use the divested assets to compete effectively in the relevant market. A buyer who fails this standard provides no remedy even if the divestiture mechanics are otherwise properly executed.

The agency's buyer approval process begins with the parties' submission of a proposed buyer, accompanied by detailed information about the buyer's financial resources, operational capabilities, existing competitive position, and plans for the divested business. The agency conducts a customer and market participant check, contacting customers of the divested business, rival suppliers, and industry participants to assess whether they believe the proposed buyer is capable of maintaining competitive discipline in the market. If the agency finds the proposed buyer acceptable, it formally approves the buyer and the parties proceed to closing. If the agency finds the buyer inadequate, the parties must identify an alternative buyer and repeat the process. In cases where the parties have had difficulty identifying an acceptable buyer, the agency may exercise its right to appoint a divestiture trustee.

The merging parties can elect between two approaches for presenting a buyer solution to the agency. The up-front buyer approach requires the parties to identify and obtain agency approval of a specific buyer before the consent decree is finalized or the merger is allowed to close. This approach provides the agency with confidence that the remedy is executable before it approves the transaction, and it protects the parties from a scenario where the consent decree is entered but no suitable buyer can be found. The fix-it-first approach involves negotiating and closing the divestiture to an approved buyer before the merger is submitted for clearance, presenting the agency with a transaction that has already resolved the competitive concern. Fix-it-first is attractive in transactions where the divestiture asset and buyer are clearly defined, but it requires the parties to complete a divestiture transaction before the merger is approved, which creates complexity in sequencing, closing conditions, and the allocation of risk if the merger ultimately does not close. For context on how deal structures affect the overall transaction, see M&A deal structures and asset purchase vs. stock purchase considerations.

Divestiture Agreement Protections: Seller Obligations and Best-Efforts Covenants

The divestiture agreement between the parties and the approved buyer is a separate M&A transaction that must be negotiated, executed, and closed alongside the primary merger. It raises a distinct set of legal and commercial issues, including the scope of representations and warranties about the divested business, indemnification obligations, closing conditions, and transition arrangements. The consent decree or order typically specifies the minimum requirements for the divestiture agreement and may require agency approval of the final terms.

Best-efforts covenants are a central element of divestiture agreements and consent decrees. The parties are typically required to use their best efforts, or in some decrees their reasonable best efforts, to complete the divestiture within the required period, to obtain all necessary third-party consents, to cooperate with the buyer's due diligence and integration planning, and to transition the business in a manner that preserves its competitive value. The distinction between best efforts and reasonable best efforts is meaningful in the context of a consent decree, because best-efforts obligations may require the parties to take steps that are commercially expensive or operationally disruptive, while reasonable-best-efforts obligations may allow the parties more latitude to balance their compliance obligations against the cost of specific actions.

The seller's representations and warranties in a divestiture agreement typically cover the assets included in the divestiture package, the absence of undisclosed liabilities, the status of customer contracts and employee arrangements, the validity of intellectual property rights, and compliance with applicable law. The agency will require that the representations be sufficient to give the buyer confidence that the assets are as described and that the divestiture business can be operated as a standalone entity. Indemnification provisions must address the allocation of pre-closing liabilities between the seller and the buyer, including environmental liabilities, product liability claims, employment claims, and regulatory obligations associated with the divested business. For additional context on carve-out transaction mechanics relevant to complex divestitures, see carve-out transactions in M&A.

Hold-Separate Arrangements and Interim Preservation Obligations

The period between merger closing and divestiture closing is a period of significant operational and legal complexity. The acquiring party has closed the merger and holds the divestiture assets as part of its combined business, but the consent decree prohibits integration of those assets into the merged entity's operations until the divestiture is complete. The hold-separate arrangement governs this interim period and is one of the most practically demanding elements of antitrust remedy compliance.

A hold-separate arrangement requires the acquirer to maintain the divestiture assets as an operationally independent unit, to refrain from sharing competitively sensitive information between the divestiture business and the rest of its organization, to appoint an independent hold-separate manager with day-to-day operational authority over the divestiture business, and to maintain the business in its current competitive condition. The hold-separate manager is typically an executive or management team with direct operational experience in the business, operating under terms approved by the agency. The manager's primary obligation is to the agency's remedy, not to the acquirer, and the manager is expected to make operational decisions that preserve the divestiture business's competitive position even when those decisions might conflict with the acquirer's broader interests.

Firewall requirements within the hold-separate arrangement prohibit the sharing of customer information, pricing data, product development plans, and other competitively sensitive information between the divestiture business and the rest of the merged entity. Firewalls must be implemented through a combination of physical separation, access restrictions, and employee training, and compliance must be documented and reported to the monitoring trustee. The monitoring trustee conducts periodic audits of firewall compliance and reports any violations to the agency. Common violations include the inadvertent sharing of information through shared IT systems, consolidated procurement arrangements, and management reporting structures that allow executives with responsibility for both the divestiture business and the retained business to access information from both units.

Monitor Trustees and Divestiture Trustees: Roles and Authority

Consent decrees in contested merger cases typically require the appointment of one or more trustees with defined roles in ensuring compliance with the decree's terms. The two principal trustee roles are the monitoring trustee and the divestiture trustee, and they perform distinct functions at different stages of the remedy process.

The monitoring trustee serves as the agency's eyes and ears throughout the divestiture process and, in cases involving behavioral remedies, throughout the compliance period. The monitoring trustee has access to the merged entity's books, records, personnel, and facilities to the extent necessary to assess compliance. The trustee conducts periodic compliance reviews, interviews hold-separate managers and key employees, reviews financial reporting for the divestiture business, and reports its findings to the agency at defined intervals. If the monitoring trustee identifies a potential violation, it typically notifies the parties and gives them an opportunity to remediate before reporting to the agency, though serious or willful violations may be reported immediately. The monitoring trustee is compensated by the parties at rates approved by the agency and is expected to operate independently of the parties' interests.

The divestiture trustee assumes active control of the divestiture process when the parties fail to identify and close a divestiture to an acceptable buyer within the period provided for the parties' own divestiture effort. The consent decree typically provides a defined period, often six to twelve months after the merger closes, for the parties to market the divestiture assets, identify a buyer, obtain agency approval, and close the divestiture. If the parties fail to complete the divestiture within that period, the decree automatically triggers the appointment of a divestiture trustee, who takes over the marketing and sale process with full authority to negotiate with prospective buyers and to close the divestiture without further consent from the parties. The divestiture trustee's authority is broader than a typical investment banker's mandate: the trustee can accept terms that the parties would not voluntarily accept and can proceed on a timeline driven by the agency's interests rather than the parties' commercial preferences.

Behavioral Remedies: MFN, Firewalls, Access, Non-Discrimination, and Licensing

When structural remedies are unavailable or insufficient, or when the competitive concern arises from a vertical relationship rather than a horizontal overlap, the agencies turn to behavioral remedies. The range of available behavioral remedies is broad, and the appropriate remedy depends on the specific theory of harm identified in the agency's competitive analysis.

Most-favored-nation provisions prohibit the merged entity from offering more favorable terms to itself or its affiliates than it offers to similarly situated third parties for access to a platform, input, or service. MFN provisions are most commonly used in platform and vertical integration cases where the merged entity controls a bottleneck resource that its downstream competitors require. The MFN obligation ensures that the merged entity cannot use its control of the bottleneck to advantage its own downstream operations at the expense of rival downstream competitors. MFN provisions require a mechanism for defining what constitutes equivalent terms and for resolving disputes about whether specific commercial arrangements comply with the MFN obligation.

Non-discrimination conduct remedies require the merged entity to offer access to inputs, distribution channels, or services on terms that do not discriminate against rivals. They differ from MFN provisions in that they do not require the merged entity to give third parties the same terms as its own affiliates; they require that the terms offered to rivals not be less favorable than the terms offered to similarly situated third parties. Access to rival remedies require the merged entity to provide rivals with access to a facility, technology, or service that they need to compete and that the merger would otherwise allow the merged entity to withhold. These remedies are most common in network industries where a key input is essential to competition and cannot be replicated by rivals within a reasonable period. Technology licensing remedies require the merged entity to license specified intellectual property on fair, reasonable, and non-discriminatory terms, typically abbreviated as FRAND. FRAND licensing remedies are used when the merged entity holds patents or other IP that rivals require to compete and that the merger would otherwise allow the merged entity to refuse to license or to license on terms that foreclose competition.

Consent Decree Approval: Tunney Act and FTC Section 5(b) Process

The procedural path to an effective consent decree differs between the DOJ and FTC, reflecting the structural differences between the two agencies and the legal frameworks governing their enforcement activities.

For DOJ consent decrees, the Tunney Act requires that the proposed decree be filed with a federal district court and subjected to a mandatory public comment period before the court can enter judgment approving it. The DOJ simultaneously files the antitrust complaint and the proposed consent decree, along with a competitive impact statement that explains the alleged violation and the DOJ's analysis of why the proposed remedy is in the public interest. The decree and competitive impact statement are published in the Federal Register, and a sixty-day public comment period follows during which any person may submit written comments to the DOJ. After the comment period, the DOJ publishes a response to the comments and files any modifications to the proposed decree it considers appropriate in light of the comments. The court then independently reviews the proposed decree and determines whether it is in the public interest. The Tunney Act's public interest standard has been interpreted by courts to require a meaningful review of the decree's competitive adequacy, but courts have generally been reluctant to reject proposed decrees unless they find the remedy manifestly inadequate.

For FTC consent orders, the process is governed by the FTC Act rather than the Tunney Act. When the FTC has negotiated a consent agreement with the parties, it issues the agreement as a proposed order and subjects it to a thirty-day public comment period. After the comment period, the Commission votes on whether to make the order final. Unlike the DOJ Tunney Act process, the FTC's consent order process does not require judicial approval; the Commission has independent authority to issue final orders. However, FTC final orders can be challenged in federal court if the affected party contests the Commission's authority or the substantive adequacy of the remedy. FTC orders are enforced through the Commission's administrative enforcement authority and through civil penalty actions in federal court for knowing violations. For context on how merger structure affects antitrust exposure and remedy negotiations, see our guide on M&A transaction services.

Compliance Monitoring, Breach Penalties, and Remedy Sunset

Antitrust consent decrees and FTC orders establish ongoing compliance obligations that can run for a decade or more after the merger closes. Effective compliance requires a structured internal program, regular engagement with the monitoring trustee, and careful attention to the decree's specific requirements. Compliance failures can result in severe financial penalties and remedial orders that are more disruptive than the original remedy.

Civil penalties for DOJ consent decree violations are enforced through contempt proceedings, which can result in daily fines for continued violations and compensatory damages for harm caused by the breach. For FTC final orders, Section 5(l) of the FTC Act authorizes civil penalties per violation per day for knowing violations. The definition of "knowing" violation has been interpreted to include situations where the party knew or should have known that its conduct violated the order's terms, not just situations where the party acted with specific intent to violate. This standard means that compliance cannot rely solely on good faith efforts; it requires a systematic review of all relevant conduct against the order's specific requirements. The risk of private damages actions under Section 4 of the Clayton Act is an additional compliance incentive. Third parties who are harmed by a consent decree violation, including customers, competitors, or business partners who were supposed to benefit from the decree's terms, may have standing to bring a private antitrust action for treble damages and attorney's fees.

Remedy sunset provisions specify the duration of the consent decree and the conditions under which it terminates. DOJ consent decrees historically ran for ten years, though more recent decrees have varied in length depending on the nature and complexity of the competitive concern. FTC consent orders historically ran for twenty years but have been issued in shorter durations in recent cases. Parties may petition the agency for early termination of a consent decree if circumstances have changed materially and the remedy is no longer necessary to protect competition. The standard for early termination is typically that changed competitive conditions have eliminated the concern the remedy was designed to address. Parties may also petition for extension of a decree's duration if compliance has been incomplete or if the competitive conditions the decree was designed to protect have not fully developed. Consent decree extensions have been granted in cases where divestiture buyers failed to achieve competitive viability within the expected timeframe.

Global Coordination, Private Damages, and Lessons from Failed Remedies

Large cross-border transactions require antitrust clearance from multiple jurisdictions, each of which may identify its own competitive concerns and impose its own remedy conditions. The coordination of global remedies is one of the most complex elements of multinational M&A execution, and the failure to manage that coordination effectively can result in remedy conditions that are inconsistent across jurisdictions, that require divestitures of overlapping or conflicting asset packages, or that impose behavioral obligations that are incompatible with the merged entity's ability to operate as an integrated global business.

The European Commission, which reviews transactions affecting the European Economic Area, operates under a separate merger regulation and applies its own analytical framework for identifying competitive concerns and designing remedies. EC remedies frequently run in parallel with U.S. remedy negotiations in major global transactions, and the agencies engage in informal coordination through established bilateral cooperation channels. The practical effect of this coordination is that the parties must present consistent remedy proposals to multiple agencies while accommodating each agency's independent assessment of the competitive harm. In some transactions, non-U.S. agencies impose more expansive remedy requirements than U.S. regulators, requiring global asset divestitures that affect markets where U.S. regulators identified no concern. Parties must evaluate the combined effect of all required remedies on the deal's economic rationale at the outset, not after individual agency decisions have been made.

The history of antitrust remedy design is punctuated by instructive failures that produced lasting changes in agency policy. In the AT&T/Time Warner vertical merger case, the DOJ chose to litigate rather than accept behavioral remedies, a decision that reflected the agency's skepticism of conduct orders in vertical integration cases. After losing the case in district court and on appeal, the DOJ's posture in subsequent vertical merger proceedings shifted, but the litigation itself demonstrated that the agency was willing to impose substantial costs on the merging parties rather than accept remedies it considered inadequate. In the Sysco/US Foods case, the FTC identified competition concerns in the foodservice distribution market and rejected the parties' proposed divestiture package as insufficient to create a viable competitor, ultimately leading to the transaction's abandonment. That outcome reinforced the agency's position that divestiture packages must be genuinely capable of restoring competition, not structured to minimize disruption to the primary transaction. Cases involving healthcare insurance consolidation, including proposed mergers among major health insurers, produced FTC challenges that demonstrated the agency's willingness to require divestitures of core business assets rather than accept narrowly scoped packages. These precedents inform current remedy negotiations and should be incorporated into antitrust risk assessments at the transaction structuring stage. See our companion analysis of the Second Request investigation process for additional context on how investigations that precede remedy negotiations are conducted, and the HSR Antitrust M&A Legal Guide for the full analytical framework.

Frequently Asked Questions